<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03171142</url>
  </required_header>
  <id_info>
    <org_study_id>R/17.01.55</org_study_id>
    <nct_id>NCT03171142</nct_id>
  </id_info>
  <brief_title>Effect of Heliox on RSV Bronchiolitis</brief_title>
  <official_title>Effect of Heliox on Infants With Respiratory Syncytial Virus Acute Bronchiolitis-A Revisit Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wael Seliem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University Children Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helium is an inert gas with a density almost one-seventh of that of air. Based on its
      properties breathing a mixture of helium and oxygen (heliox) will lead to a reduction in
      resistance through narrowed airways and consequently decreases the work of breathing.
      Participating infants with RSV acute bronchiolitis will be supplied with heliox (ration of 21
      oxygen and 79 helium) delivered through a flow nasal cannula to evaluate heliox effect in
      improving their oxygenation. Heliox will act as an additive therapy to improve oxygenation in
      patients with lower respiratory tract infection caused by respiratory Syncytial Virus (RSV)
      and will decrease the need for more complicated therapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Actual">May 1, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in oxygenation</measure>
    <time_frame>change from baseline at 24 hours after treatment</time_frame>
    <description>Arterial blood samples will be withdrawn through an arterial stab to determine partial pressure of arterial oxygen (PaO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of respiratory distress</measure>
    <time_frame>change from baseline at 24 hours after treatment</time_frame>
    <description>measured by the Modified Wood's Clinical Asthma Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>RSV Infection</condition>
  <condition>Acute Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>Heliox group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive Helium oxygen mixture 21:79 via nasal cannula 2L/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Air group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive oxygen 21%via nasal cannula 2L/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heliox</intervention_name>
    <description>Heliox (21:79) via nasal cannula 2 litter per minutes</description>
    <arm_group_label>Heliox group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Air</intervention_name>
    <description>Air 21% via nasal cannula 2 litter per minutes</description>
    <arm_group_label>Air group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age fro 1 month till 2 years

          -  RSV acute bronchiolitis without any supplemental oxygen.

        Exclusion Criteria:

          -  oxygen supplement or mechanical ventilation requirement

          -  congenital anomalies of the heart

          -  chronic lung disease including bronchopulmonary dysplasia

          -  Failure to obtain an informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University Children Hospital</investigator_affiliation>
    <investigator_full_name>Wael Seliem</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>Heliox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

